Glaxo Ziagen/AZT/3TC Combo Appropriate For Second-Line Use, Cmte. Says
Executive Summary
A triple nucleoside combination containing Glaxo Wellcome's Ziagen plus AZT and 3TC would be useful as a second-line therapy in HIV patients for whom protease inhibitors are contraindicated, members of FDA's Antiviral Drugs Advisory Committee suggested Nov. 2.